![Zydus Cadila gets tentative approval for generic diabetes drug Zydus Cadila gets tentative approval for generic diabetes drug](https://images.cnbctv18.com/wp-content/uploads/2020/06/ZydusCadila1-1019x573.jpg?impolicy=website&width=590&height=264)
Drug firm Zydus Cadila on Wednesday said it has received approval from the US health regulator to market diabetes drug, Empagliflozin and Linagliptin tablets, in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) to market its generic product, Zydus Cadila said in a statement.
The company has received approval for the product in the strengths of 10 mg/5 mg and 25 mg/5 mg, it added.
This medication contains a combination of Empagliflozin and Linagliptin, oral diabetes medicines that help control blood sugar levels.
The drug is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Zydus said the drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 299 approvals and has so far filed over 390 abbreviated new drug applications (ANDAs) since the commencement of filing process in 2003-04, it added.
First Published: Sept 9, 2020 4:30 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
![](/static/images/loksabha2024/loksabha2024.png)
![](/static/images/loksabha2024/loksabha2024.png)
Odisha's new CM — who is Mohan Charan Majhi and what prompted the BJP to choose him
Jun 13, 2024 2:54 PM
Election 2024: 504 out of 543 newly-elected MPs are ‘crorepatis’ – Check 10 richest members in 18th Lok Sabha
Jun 12, 2024 9:55 PM
BJP to start nationwide organisational rejig, new party president to be elected soon
Jun 12, 2024 9:31 AM
New Lok Sabha Speaker to be elected in special 8-day session: Report
Jun 11, 2024 6:28 PM